Ancora Heart has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the Accucinch ventricular restoration system.
Currently being evaluated in the CORCINCH-HF pivotal clinical trial, the Accucinch system is designed to provide a minimally invasive treatment option for patients who have symptomatic heart failure (HF) with reduced ejection fraction (HFrEF).
“The chronic and progressive nature of heart failure leaves many patients to face an increasingly challenging future as existing treatments, including medications and pacemaker devices, are not able to keep the disease at bay,” said Ulrich P Jorde (Montefiore Health System, New York, USA) and global co-principal investigator of the CORCINCH-HF Study. “Early data on the Accucinch System are promising, providing hope that this novel transcatheter approach may address the therapeutic gap for heart failure patients in the future.”
Source CardiovascularNews
Duc Tin Clinic
Tin tức liên quan
Performance diagnostique de l’interféron gamma dans l’identification de l’origine tuberculeuse des pleurésies exsudatives
A Mixed Phenotype of Airway Wall Thickening and Emphysema Is Associated with Dyspnea and Hospitalization for Chronic Obstructive Pulmonary Disease.
Radiological Approach to Asthma and COPD-The Role of Computed Tomography.
Significant annual cost savings found with UrgoStart in UK and Germany
Thrombolex announces 510(k) clearance of Bashir catheter systems for thromboembolic disorders
Phone: (028) 3981 2678
Mobile: 0903 839 878 - 0909 384 389